SCHEMBL4472145

SCHEMBL4472145

O=C(CBr)c1cc(Cl)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 5/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
FOLH1 Q04609 1/20 0.47
PTGER1 P34995 2/20 0.46
MCL1 Q07820 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HPGD P15428 3/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MITF O75030 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20445937 0.92 MRGPRX4 (0.50) MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL383618 0.88 FOLH1 (0.58) MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL13627471 0.85 NR4A2 (0.45) MRGPRX4ALDH1A1CYP1A2CYP2C19MCL1
SCHEMBL4483528 0.84 ABCB1 (0.48) KDM4EALDH1A1FOLH1RAB9ASMN1; SMN2
SCHEMBL2469286 0.84 MRGPRX4 (0.52) MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL11355488 0.83 PTGER1 (0.54) MRGPRX4FOLH1PTGER1MCL1NPC1
SCHEMBL384030 0.83 MAOB (0.57) MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL21437076 0.82 MCL1 (0.50) KDM4EALDH1A1CYP2C9CYP2C19FOLH1
SCHEMBL11751536 0.81 MEN1 (0.62) MRGPRX4ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL21327265 0.81 ALDH1A1 (0.56) MRGPRX4KDM4EALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 US disclosed
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 US disclosed
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 US disclosed
US-20060148817-A1 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2006-07-06 US disclosed
EP-1572664-A1 PYRAZOLE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2005-09-14 EP disclosed
WO-2004056782-A1 PYRAZOLE COMPOUNDS VERNALIS (CAMBRIDGE) LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148817-A1 Pyrazole compounds NRAS, HSP90AB1, HSP90AA1 MRGPRX4 2636/4885KDM4E 4792/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.